NightstaRx
Employee Participants0
Total Rating0
Revenue$0
Developer of a gene therapy designed to maintain and restore sight in patients with inherited retinal dystrophies. The company's gene therapy is potentially a sight restoring therapy for a rare degenerative disease causing blindness known as Choroideremia, enabling patients to get treated for several rare conditions caused by mutations in a single gene. Read More
Headquarters Wellcome Gibbs Building, London, NW1 2BE, GBR
Website www.nightstarx.com
0/100